ROVI presents its financial results for the first quarter of 2026, a year in which the Company expects to resume a path of growth, supported by the key strategic decisions taken over recent years.
REVENUES
Total revenue stood at €154.7 million in the first quarter of 2026. ROVI booked operating revenue of 152.5 million euros, representing a 2% decrease on the first quarter of 2025 due to the behaviour of the heparin franchise. Notwithstanding, the contract manufacturing business (CDMO) recorded sales of 37.4 million euros, a 5% increase on the first quarter of 2025.
The sales of the specialty pharmaceutical business stood at €115.0 million in the first quarter of this year.
Sales of the low-molecular-weight heparin franchise dropped 13% to 58.9 million euros, due to a lower contribution from bemiparin, particularly in international sales, as a result of the high inventory levels held by partners.
Risperidone ISM stands out, with sales reaching 17.2 million euros, showing growth of 37% compared with the same quarter of 2025.
Solid performance of Neparvis®, with sales growing by 4% in the first quarter of this year.
Gross profit increased 5% to 95.0 million euros in the first quarter of 2026 compared with the first quarter of 2025, reflecting a 3.8 percentage point increase in the gross margin, which rose to 62.3%.
EBITDA stood at 20.3 million euros in the first quarter of 2026. This has led to a 6.3 percentage point reduction in the EBITDA margin to 13.3%. Net profit stood at 9.4 million euros.
R&D expenses rose 75% in the first quarter of 2026 compared with the same period of last year. This increase relates mainly to preparations for the phase III clinical trial of Letrozole SIE.
ROVI has updated its operating revenue guidance for 2026 . expecting them to continue to increase compared to 2025, although by a low- to mid-single-digit percentage. Factors taken into account for this revision include:
- Firstly, lower revenue forecast for 2026 under the prefilled syringe manufacturing agreement entered into with a global pharmaceutical company on 25 April 2024. The adjustment to the guidance is due, among other factors, to a delay in the initially expected commencement of routine manufacturing operations, which is awaiting the relevant regulatory authorization, as well as increased uncertainty regarding anticipated demand, without prejudice to the minimum contractual obligations assumed by the two parties; and
- Secondly, growing competitive pressure on pricing in the heparin franchise in the current context of increased regulatory and geopolitical uncertainty and greater volatility in supply and cost dynamics.